News

AIN Ventures and VIPC Invest in Cerbrec to Accelerate AI Innovation

Cerbrec, a leading Virginia-based AI platform provider, announced that AIN Ventures has invested in its seed funding round. This investment will enable Cerbrec to accelerate its mission of equipping biotech and pharmaceutical companies, along with those in other industries, with cutting-edge tools for creating tailored AI solutions.

Cerbrec’s flagship product, Graphbook, is an innovative drag-and-drop AI platform that allows subject matter experts to design advanced, customized AI solutions without the need for coding or prior AI development experience. Graphbook effectively tackles critical challenges in AI development, such as reducing technical barriers, shortening time to delivery, and improving AI transparency for review and documentation, all while ensuring compliance with regulations.

“We are redefining the AI development process by empowering everyone to create bespoke AI solutions using natural language or drag-and-drop,” said Garrett Wang, CEO of Cerbrec. “This new funding allows us to enhance our platform and expand its reach across biotech, pharma, higher education, and beyond. We are excited to partner with investors who share our passion for pushing the boundaries of AI and are grateful for the support that will help us make a lasting impact on both the AI landscape and the broader technology ecosystem.”

Cerbrec stands out in the AI landscape due to its intuitive visual programming interface while also accepting natural language queries. This combination lets non-coder users without prior AI development experience easily design complex AI workflows, and organizations quickly create and deploy AI solutions that are tailored to their specific needs and use cases. Furthermore, Cerbrec prioritizes AI model transparency, auditability, and regulatory compliance with its solution.

Seed funding will be strategically allocated to expand the Cerbrec team, focusing on engineering and customer success roles, speeding up product development and feature enhancements for Graphbook, and scaling go-to-market efforts in the biotech and pharmaceutical sectors.

“Cerbrec’s approach to AI development is truly transformative. By putting the power of AI development directly into the hands of domain experts, they are unlocking the potential for innovation across many industries,” said Sherman Williams, Co-Founder and Managing Partner of AIN Ventures.

AIN Ventures’ investment in Cerbrec was carried out in collaboration with Virginia Innovation Partnership Corporation (VIPC)’s Virginia Venture Partners (VVP) and its Virginia Invests fund of funds initiative. Launched in 2024, Virginia Invests has taken LP positions in six fund managers, including AIN Ventures, to accelerate the infusion of capital into Virginia startups and generate new opportunities for Virginia entrepreneurs to grow and innovate. The program, powered by the U.S. Department of Treasury State Small Business Credit Initiative (SSBCI), is designed to catalyze over $250 million in investments over the next 3-5 years.

“AIN Ventures and VIPC share a unified commitment to advancing innovation and driving economic growth in Virginia by strategically focusing on emerging technologies and empowering visionary entrepreneurs to bring transformative ideas to life,” said Aurelia Flores, Director of the Virginia Invests program. “This investment into Cerbrec is a prime example of how the Virginia Invests program is helping fuel the growth of pioneering startups. We are proud to partner with AIN Ventures in this exciting journey, reinforcing Virginia’s role as a leader in innovation and creating an environment where startups like Cerbrec can thrive.”

Joining AIN Ventures in Cerbrec’s funding round are SRI International, Inner Loop Capital, Gurtin Ventures, among others, underscoring strong investor confidence in Cerbrec’s vision. Cerbrec is also part of the AWS Generative AI accelerator and Techstars Boston.

 

Read more here.

Recent News

10/27/2025

Virginia can lead biotech manufacturing renaissance – if policymakers help

Last week, pharmaceutical giant Merck broke ground on a new $3 billion facility in Virginia that will create 8,000 construction jobs and 500 permanent manufacturing jobs. The new 400,000 square-foot, state-of-the-art plant isn’t merely the latest addition to Virginia’s rapidly growing biotech industry footprint. It’s a sign that America is making quick progress towards President

10/22/2025

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program